Robbins LLP Alerts Investors About Unicycive Therapeutics Class Action Lawsuit

Investor Alert: Unicycive Therapeutics Class Action Lawsuit

Robbins LLP has issued an important alert for investors regarding a class action lawsuit that has been filed against Unicycive Therapeutics, Inc. (NASDAQ: UNCY). This litigation concerns shareholders who purchased or acquired Unicycive securities between March 29, 2024, and June 27, 2025. Unicycive, a clinical-stage biotechnology firm, is committed to developing and marketing therapies aimed at addressing significant unmet medical needs in the U.S.

Overview of the Allegations

The firm, Robbins LLP, is investigating claims that Unicycive Therapeutics may have misled investors about the readiness of its drug prospect, specifically the New Drug Application (NDA) for oxylanthanum carbonate (OLC). This drug is intended for treating hyperphosphatemia among chronic kidney disease patients undergoing dialysis.

According to the allegations outlined in the complaint, Unicycive highlighted the potential of their NDA and assured investors of its capability to meet the manufacturing compliance standards set by the U.S. Food and Drug Administration (FDA). However, the lawsuit claims that these assurances were misleading, as it later came to light that the company's readiness to meet FDA standards was greatly exaggerated.

On June 10, 2025, Unicycive disclosed that the FDA had identified significant deficiencies in Current Good Manufacturing Practice (cGMP) compliance at one of their third-party manufacturing vendors, which prompted an FDA inspection. Because of these identified compliance issues, any discussions regarding the drug labels with the FDA were suspended. Following this announcement, Unicycive's stock plummeted over 40%.

Further exacerbating the situation, on June 30, 2025, the company announced that it had received a Complete Response Letter from the FDA regarding the OCL NDA, again referencing the cGMP deficiencies at their subcontractor’s manufacturing site. This subsequent announcement caused the stock to fall nearly 30%, closing at $4.77 per share.

Taking Action

Investors who believe they may be affected by these developments may be eligible to take part in the class action against Unicycive Therapeutics, Inc. Shareholders interested in serving as lead plaintiffs in the case should reach out to Robbins LLP before the impending deadline of October 14, 2025. The lead plaintiff serves as a representative for other class members during litigation, although it is not necessary to participate in the lawsuit to be eligible for a potential recovery.

All representation provided by Robbins LLP is on a contingency fee basis, meaning clients will incur no upfront fees or expenses related to the lawsuit.

About Robbins LLP

Established in 2002, Robbins LLP has built a reputation as a leader in protecting shareholder rights through litigation. The firm goes to great lengths to help shareholders recover losses, enhance corporate governance, and hold company executives accountable for any misconduct.

To receive notifications concerning the settlement of this class action or alerts regarding other corporate misconduct, interested parties are encouraged to sign up for Stock Watch today.

In conclusion, it’s essential for shareholders to stay informed and consider their options in light of recent developments surrounding Unicycive Therapeutics. If you believe you have been affected by potential discrepancies in the company's reporting and drug development announcements, consulting with Robbins LLP may be the first step towards seeking justice and recovery.

Important Note: Attorney advertising; past results do not guarantee similar outcomes.